These products will be the first oral solid oncology products for Armas.
|
MANALAPAN, N.J., April 8, 2019 /PRNewswire/ -- Armas Pharmaceuticals, Inc. is pleased to announce the release of its second and third generic products, Capecitabine and Imatinib, for the U.S. market. These products will be the first oral solid oncology products for Armas. Capecitabine will be available in strengths of 100 mg and 400 mg and Imatinib will be available in strengths of 150 mg and 500 mg. "Following the launch of our first oncology injectable, Azacitidine for injection, in late 2018, Armas Pharmaceuticals is excited to announce the launch of our first two oral oncology products to the market. Imatinib and Capecitabine expands on Armas's goal to bring high quality, affordable pharmaceuticals to the US market," says John Niemi, President & CEO of Armas. Capecitabine, an AB-rated generic equivalent to the brand Xeloda® (a trademark of Hoffman-La Roche, Inc), generated annual sales of approximately $108 million with the year ending December 31, 2018, according to sales data. Imatinib Mesylate, an AB-rated generic equivalent to the brand Gleevec® (a trademark of Novartis AG Corporation), generated annual sales of approximately $655 million with the year ending December 31, 2018, according to industry sales data. About Armas Pharmaceuticals, Inc. Contact:
SOURCE Armas Pharmaceuticals, Inc. |
View original content:
